1. Patient-derived models are crucial for drug and target discovery testing as heterogeneity is significant in TNBC.
  2. Using a low-dose drug combination to inhibit kinase signaling networks is a novel and effective treatment strategy for TNBC metastasis.
  3. Review how artificial intelligence tools can be used to create digital biomarkers from pathologic images.
  4. Discuss open-source software and its important for medical AI research.
Session date: 
05/23/2023 - 12:00pm to 1:00pm CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Margarite Matossian and James Dolezal